Clinical Trials
Thermo Fisher Scientific Expands Global Footprint to Support Cell and Gene Therapy Clinical Trials in Japan
Thermo Fisher Scientific, the world leader in serving science announced the expansion of its Fisher BioServices cryogenic service capabilities in Japan. This expansion enables its customers to seamlessly conduct clinical trials across multiple geographies and provides...
Clinical Trials
Sun Pharma announces the Phase 3 results of investigational psoriasis medicine
Sun Pharma has announced late-breaking data from two pivotal Phase-3 clinical trials (reSURFACE 1 and 2) achieving the primary endpoint with tildrakizumab, an investigational IL-23p19 inhibitor, in patients with moderate-to-severe plaque psoriasis at the 25th European Academy of Dermatology...
Clinical Trials
AbbVie’s Investigational HCV Regimen Receives U.S. FDA Breakthrough Therapy Designation
AbbVie a global biopharmaceutical company announced that the U.S. FDA has granted Breakthrough Therapy Designation (BTD) for the investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P) for the treatment of patients with chronic hepatitis C virus (HCV) who failed...
Clinical Trials
Genocea’s Immunotherapy GEN-003 Demonstrates Significant Reduction of Viral Shedding in Phase 2b Clinical Trial
Genocea Biosciences, a biopharmaceutical company developing T cell-directed vaccines and immunotherapies announced positive results from its ongoing Phase 2b trial evaluating a new Phase 3-ready formulation of GEN-003 for the treatment of genital herpes. The study...
Clinical Trials
Threshold Announces Interim Results from Tarloxotinib Program and its Plans to Focus on Evofosfamide and Earlier-Stage Opportunities
Threshold Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company specializing in the development of novel pharmaceutical products and technologies for the treatment of cancer, announced interim data from its two Phase 2 proof-of-concept clinical trials of tarloxotinib Outlined...
Clinical Trials
Novartis announces AMG 334 significantly reduces monthly migraine days in people with episodic migraine
Novartis announced positive topline results from ARISE, the first Phase III study evaluating the efficacy and safety of monthly subcutaneous AMG 334 (erenumab) 70mg in episodic migraine prevention. The study met the primary endpoint, demonstrating a...
Clinical Trials
Advaxis Inc starts New Manufacturing/Laboratory Facility in Princeton
Advaxis, Inc a clinical stage biotechnology company developing cancer immunotherapies, will unveil its new state-of-the-art manufacturing facility in Princeton, N.J., with remarks from Governor Chris Christie, BioNJ President and CEO Debbie Hart and Advaxis CEO Daniel O’Connor. ...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
